IN8bio, Inc. Common Stock
Symbol: INAB (NASDAQ)
2.02
▲ (5.50%) 0.105
Company Description:
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Key Stats
- Today's Open: $1.93
- Today's High: $2.21
- Today's Low: $1.95
- Today's Volume: 9.87K
- Yesterday Close: $1.91
- Yesterday High: $2.04
- Yesterday Low: $1.91
- Yesterday Volume: 69.37K
- Last Min Volume: 6
- Last Min High: $2.015
- Last Min Low: $2.015
- Last Min VWAP: $2.015
Company Profile
- Name: IN8bio, Inc. Common Stock
- Website: https://www.in8bio.com
- Listed Date: 2021-07-30
- Location: NEW YORK, NY
- Market Status: Active
- CIK Number: 0001740279
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $8.67M
- Round Lot: 100
- Outstanding Shares: 4.54M
- Asset Type: CS
RECENT FILINGS FOR INAB
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | SCHEDULE 13G/A | View |
| 2025-08-13 | SCHEDULE 13G/A | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-07-29 | SCHEDULE 13G/A | View |
| 2025-06-30 | 8-K | View |
| 2025-06-04 | 8-K | View |
| 2025-06-02 | 8-K | View |
| 2025-05-12 | 4 | View |
| 2025-05-12 | 4 | View |
| 2025-05-12 | 4 | View |
| 2025-05-12 | 4 | View |
| 2025-05-12 | 4 | View |
| 2025-05-12 | 4 | View |
| 2025-05-09 | 8-K | View |
| 2025-05-08 | SCHEDULE 13D/A | View |
| 2025-05-07 | 4 | View |
| 2025-05-07 | 4 | View |
| 2025-05-07 | 4 | View |
Latest News on INAB